Swiss biotech company Stalicla has signed a licensing deal with Evgen Pharma for the latter’s lead asset, SFX-01, in neurodevelopmental disorders and schizophrenia.
Under the deal, Stalicla will gain the global rights of SFX-01 as a potential treatment for autism spectrum disorder (ASD), while Evgen will retain SFX-01’s worldwide rights for all other indications.
Go deeper with GlobalData
As per the terms of the licencing agreement, Evgen will receive an upfront payment of $0.5m, followed by a further $0.5m at the conclusion of the completely financed Phase I study.
Up to commercial launch, the company will also receive $26.5m in milestone payments that include $5m upon receipt of the investigational new drug (IND) from the US Food and Drug Administration (FDA), which is expected late next year.
Evgen will receive $160.5m in total milestones that are payable in relation to the first neurodevelopmental disorder indication under the licence deal.
See Also:
SFX-01 is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIt is claimed to be the only grade of sulforaphane which is suitable for clinical research and will eventually be approved as a medicine.
SFX-01 has been identified by Stalicla as the treatment candidate for ASD-Phenotype 2, the company’s second subgroup of patients.
Evgen CEO Dr Huw Jones said: “This is an exciting opportunity to work with Stalicla to develop a potential treatment for ASD and other neuropsychiatric disorders.
“There are no current approved treatments for ASD, but a molecular target activated by SFX-01 offers considerable promise in alleviating some of the complex behavioural challenges experienced by people with these conditions.
“This recognition of SFX-01 as a potential treatment for a major neuropsychiatric condition demonstrates the variety of potential uses of our Sulforadex platform, along with our ability to execute our business model.”
The company stated that the collaboration with Stalicla will allow it to target patient groups that are likely to benefit from SFX-01, therefore de-risking the clinical development.
It will also potentially bring a therapeutic option quickly for currently underserved individuals.
Additionally, Evgen will partner with Stalicla on a clinical programme focused on ASD, with funding for all clinical development activities to come from Stalicla.
